var data={"title":"Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in neonates: Evaluation and management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in neonates: Evaluation and management</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H4185297313\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The evaluation and management of suspected <em>Staphylococcus aureus</em> or streptococcal skin and soft tissue infections (SSTIs) in neonates (&le;28 days of age) are discussed here. Clinical features of SSTI; the evaluation and management of staphylococcal and streptococcal SSTIs in children older than 28 days; the epidemiology, prevention, and control of methicillin-resistant <em>S. aureus </em>(MRSA) infections in children; and the treatment of invasive MRSA infections in children are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant#H6\" class=\"medical medical_review\">&quot;Vesiculopustular and bullous lesions in the newborn and infant&quot;, section on 'Bacterial infection'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=neonatal-and-infantile-erythroderma#H1045878400\" class=\"medical medical_review\">&quot;Neonatal and infantile erythroderma&quot;, section on 'Infectious diseases'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-children-greater-than28-days-evaluation-and-management\" class=\"medical medical_review\">&quot;Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in children &gt;28 days: Evaluation and management&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-prevention-and-control\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus in children: Prevention and control&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3022346934\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most bacterial skin and soft tissue infections (SSTIs) in neonates are caused by <em>S. aureus</em>. Group B <em>Streptococcus</em> occasionally causes cellulitis. Group A streptococcal SSTIs in neonates are uncommon but may occur. (See <a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant#H6\" class=\"medical medical_review\">&quot;Vesiculopustular and bullous lesions in the newborn and infant&quot;, section on 'Bacterial infection'</a> and <a href=\"topic.htm?path=neonatal-and-infantile-erythroderma#H1045878400\" class=\"medical medical_review\">&quot;Neonatal and infantile erythroderma&quot;, section on 'Infectious diseases'</a> and <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H19\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Other focal infection'</a>.)</p><p class=\"headingAnchor\" id=\"H82810968\"><span class=\"h1\">EVALUATION</span></p><p class=\"headingAnchor\" id=\"H4050619578\"><span class=\"h2\">History and examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical evaluation of the neonate with suspected bacterial skin and soft tissue infection (SSTI) focuses on identification of systemic infection and clinical manifestations of conditions that require management that differs from that of staphylococcal or streptococcal SSTI in neonates. These conditions often are associated with vesicopustular skin lesions (<a href=\"image.htm?imageKey=PEDS%2F75417\" class=\"graphic graphic_table graphicRef75417 \">table 1</a>). (See <a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant\" class=\"medical medical_review\">&quot;Vesiculopustular and bullous lesions in the newborn and infant&quot;</a>.)</p><p>Important aspects of the clinical evaluation include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic signs or symptoms, such as fever (temperature &ge;38&deg;C [100.4&deg;F]), hypothermia (temperature &lt;35&deg;C [95&deg;F]), ill-appearance, irritability, and poor feeding</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk factors for sepsis and herpes simplex virus (HSV), which are discussed separately (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H96556694\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Maternal risk factors'</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation#H462631968\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;, section on 'Risk factors'</a> and <a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy\" class=\"medical medical_review\">&quot;Genital herpes simplex virus infection and pregnancy&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Associated features of congenital HSV, neonatal varicella virus, or congenital syphilis (<a href=\"image.htm?imageKey=PEDS%2F76743\" class=\"graphic graphic_table graphicRef76743 \">table 2</a>) (see <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H6\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Neonatal HSV'</a> and <a href=\"topic.htm?path=varicella-zoster-infection-in-the-newborn#H3\" class=\"medical medical_review\">&quot;Varicella-zoster infection in the newborn&quot;, section on 'Neonatal varicella'</a> and <a href=\"topic.htm?path=congenital-syphilis-clinical-features-and-diagnosis#H28809272\" class=\"medical medical_review\">&quot;Congenital syphilis: Clinical features and diagnosis&quot;, section on 'Early congenital syphilis'</a>)</p><p/><p class=\"headingAnchor\" id=\"H2484336351\"><span class=\"h2\">Laboratory evaluation</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gram stain, culture, and susceptibility testing of purulent material</strong> &ndash; We obtain specimens for Gram stain, culture, and susceptibility testing from neonates with <span class=\"nowrap\">purulent/fluctuant</span> skin lesions (ie, abscesses) if purulent material can be obtained [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/1-3\" class=\"abstract_t\">1-3</a>].</p><p/><p class=\"bulletIndent1\">Gram stain identification of gram-positive cocci may help to guide empiric therapy.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Gram stain identification of gram-positive cocci in clusters provides early indication of staphylococcal infection. If <em>S. aureus</em> is isolated in bacterial culture, susceptibility testing is necessary to distinguish methicillin-resistant <em>S. aureus</em> from methicillin-susceptible <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/4\" class=\"abstract_t\">4</a>]. In some laboratories, methicillin resistance may be detected rapidly using commercially available molecular tests for the mecA gene that leads to methicillin resistance. (See <a href=\"topic.htm?path=rapid-detection-of-methicillin-resistant-staphylococcus-aureus\" class=\"medical medical_review\">&quot;Rapid detection of methicillin-resistant Staphylococcus aureus&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Gram stain identification of gram-positive cocci in chains provides early identification of streptococcal infection. Culture is necessary to distinguish between group A and group B <em>Streptococcus</em>. The empiric treatment of neonatal group B streptococcal infection is discussed separately. (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H27\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Antimicrobial therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other studies</strong> &ndash; Our approach to obtaining other laboratory studies and cultures in neonates with suspected bacterial SSTI depends upon the type of infection and associated systemic findings. Systemic findings include fever (temperature &ge;38&deg;C [100.4&deg;F]), hypothermia (temperature &lt;35&deg;C [95&deg;F]), ill-appearance, irritability, and poor feeding.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Neonates with mastitis</strong> &ndash; The evaluation of neonates with mastitis is discussed separately. (See <a href=\"topic.htm?path=mastitis-and-breast-abscess-in-infants-younger-than-two-months#H11\" class=\"medical medical_review\">&quot;Mastitis and breast abscess in infants younger than two months&quot;, section on 'Additional evaluation'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Term neonates (&ge;37 weeks gestation) with localized pustulosis and no systemic findings</strong> &ndash; Localized pustulosis (<a href=\"image.htm?imageKey=PEDS%2F107272\" class=\"graphic graphic_picture graphicRef107272 \">picture 1</a>) usually is caused by <em>S. aureus</em>. We generally do not obtain blood cultures or other microbiologic studies unless it is necessary to distinguish staphylococcal pustulosis from other causes of pustular lesions (<a href=\"image.htm?imageKey=PEDS%2F75417\" class=\"graphic graphic_table graphicRef75417 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/5\" class=\"abstract_t\">5</a>]. In otherwise asymptomatic neonates with pustulosis, the Gram stain is helpful in distinguishing pustulosis from other conditions. If HSV remains a possibility, the infant should undergo full evaluation for HSV. (See <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H11\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Evaluation and diagnosis'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Preterm (&lt;37 weeks gestation), low birth weight neonates with localized pustulosis (with or without systemic findings)</strong> &ndash; We usually obtain blood cultures.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Term or preterm neonates with multiple sites of pustulosis, other types of SSTI (eg, cellulitis, abscess, mastitis), or systemic findings</strong> &ndash; We obtain blood and urine cultures in all such patients and cerebrospinal fluid (CSF) cultures as clinically indicated (eg, <span class=\"nowrap\">fever/hypothermia,</span> ill-appearing, etc) [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3\" class=\"abstract_t\">3</a>]. Indications for CSF cultures in neonates are discussed separately:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Preterm neonates (&lt;34 weeks gestation) (see <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation#H176901095\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;, section on 'Other cultures'</a>)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Term (&gt;37 weeks gestation) and late preterm (34 to 36 weeks gestation) neonates &lt;7 days (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H103627438\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Early-onset sepsis'</a>)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Term and late preterm neonates &ge;7 days of age (see <a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-outpatient-evaluation#H3091567546\" class=\"medical medical_review\">&quot;Febrile infant (younger than 90 days of age): Outpatient evaluation&quot;, section on 'Our approach'</a>)</p><p/><p class=\"bulletIndent2\">Significant CSF pleocytosis with sterile CSF culture may be seen in association with community-associated <em>S. aureus</em> infection in neonates [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3,5\" class=\"abstract_t\">3,5</a>]. The pathogenesis of the pleocytosis is unclear.</p><p/><p class=\"headingAnchor\" id=\"H1383900093\"><span class=\"h1\">MANAGEMENT APPROACH</span></p><p class=\"headingAnchor\" id=\"H3544538838\"><span class=\"h2\">Localized pustulosis</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Term neonates without systemic findings </strong>&ndash; We suggest that localized pustulosis (<a href=\"image.htm?imageKey=PEDS%2F107272\" class=\"graphic graphic_picture graphicRef107272 \">picture 1</a>) in term neonates (&ge;37 weeks gestation) without systemic findings (fever, hypothermia, ill-appearance, irritability, poor feeding) be treated with topical antibiotic therapy (eg, <a href=\"topic.htm?path=mupirocin-pediatric-drug-information\" class=\"drug drug_pediatric\">mupirocin</a> three times daily for 5 to 10 days) in the outpatient setting (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/1,3\" class=\"abstract_t\">1,3</a>]; close follow-up of such patients is imperative [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Term neonates with systemic findings</strong> &ndash; We use parenteral rather than topical therapy for full-term neonates with localized pustulosis and fever or other signs or symptoms of systemic infection (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>). (See <a href=\"#H986900721\" class=\"local\">'Choice of initial therapy'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Preterm (&lt;37 weeks gestation) low birth weight neonates</strong> &ndash; We recommend that local pustulosis in preterm (&lt;37 weeks gestation) low birth weight infants be treated parenterally at least until bacteremia is excluded (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/1\" class=\"abstract_t\">1</a>]. If blood cultures were not obtained, a five- to seven-day course of parenteral therapy is reasonable &ndash; provided that the infant continues to be clinically well and the pustulosis resolved completely. (See <a href=\"#H986900721\" class=\"local\">'Choice of initial therapy'</a> below and <a href=\"#H2391063259\" class=\"local\">'Duration of therapy'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H2566049618\"><span class=\"h2\">SSTI more severe than localized pustulosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We hospitalize neonates with skin and soft tissue infection (SSTI) more severe than localized pustulosis (eg, multiple sites of pustulosis, mastitis and other sites of cellulitis, abscess) for close monitoring and parenteral antimicrobial therapy (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3\" class=\"abstract_t\">3</a>]. In addition to provision of parenteral antimicrobial therapy, we recommend drainage of purulent or fluctuant lesions (eg, cutaneous abscess). (See <a href=\"#H986900721\" class=\"local\">'Choice of initial therapy'</a> below.)</p><p>Neonates with SSTI other than localized pustulosis are at increased risk for sepsis and invasive infection (given the immaturity of their immune system). (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;</a>.)</p><p>Clinical features and clinical decision rules cannot accurately predict serious bacterial infection in young infants. Neonates with SSTI other than localized pustulosis typically have undergone evaluation for one or more concomitant serious bacterial infection (eg, bacteremia, urinary tract infection, meningitis, osteoarticular infection) and are treated with parenteral antimicrobial therapy until 48-hour culture results are available.</p><p class=\"headingAnchor\" id=\"H2164651994\"><span class=\"h1\">ANTIMICROBIAL THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The safety and efficacy of topical, oral, and parenteral antimicrobial therapy for staphylococcal and streptococcal skin and soft tissue infection (SSTI) in neonates have not been well evaluated in clinical studies. We generally provide empiric coverage for <em>S. aureus</em> and add coverage for other pathogens as clinically indicated (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>).</p><p>Our approach to antimicrobial therapy is consistent with that provided by the Infectious Diseases Society of America [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/1\" class=\"abstract_t\">1</a>], which is based upon observations from a review of 126 cases treated between 2001 and 2006 at the author's institution [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H986900721\"><span class=\"h2\">Choice of initial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The empiric parenteral antibiotic regimen for suspected staphylococcal or streptococcal SSTI in neonates should be based upon the type of infection and local susceptibility pattern of community-associated <em>S. aureus</em> isolates. When the etiologic agent and susceptibility are known, antimicrobial therapy can be narrowed as indicated.</p><p class=\"headingAnchor\" id=\"H667914192\"><span class=\"h3\">SSTI without systemic findings</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>SSTI other than cellulitis </strong>&ndash; For neonates with SSTI other than cellulitis and no systemic findings (eg, fever, hypothermia, ill-appearance, irritability, poor feeding), we provide initial empiric coverage for methicillin-resistant <em>S. aureus</em> (MRSA) with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> or <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, given the high prevalence of MRSA in our community (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/1,3\" class=\"abstract_t\">1,3</a>]. <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> is an option in selected circumstances (eg, infection due to MRSA resistant to clindamycin in an infant with underlying renal dysfunction).</p><p/><p class=\"bulletIndent1\">In communities where MRSA is less prevalent (eg, &lt;10 to 15 percent of <em>S. aureus</em> isolates), initial empiric coverage for methicillin-susceptible <em>S. aureus</em> (MSSA) is an alternative (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>). Agents active against MSSA include <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a>, <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a>, or <a href=\"topic.htm?path=cefazolin-pediatric-drug-information\" class=\"drug drug_pediatric\">cefazolin</a>; <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">piperacillin-tazobactam</a> is an alternative if it is necessary for another indication (eg, <em>Pseudomonas</em>) (<a href=\"image.htm?imageKey=PEDS%2F107674\" class=\"graphic graphic_table graphicRef107674 \">table 3</a>). Parenteral coverage should be broadened to include MRSA, group B <em>Streptococcus</em> (GBS), and enteric gram-negative pathogens if the infant develops systemic findings and to include MRSA, GBS, and other beta-hemolytic streptococci if the infant develops cellulitis. (See <a href=\"#H3683681263\" class=\"local\">'SSTI with systemic findings'</a> below.)</p><p/><p class=\"bulletIndent1\">Studies comparing antistaphylococcal regimens in neonates with SSTI are lacking. The antibiotics suggested above are equally reasonable based upon in vitro data and clinical observations.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cellulitis</strong> &ndash; For neonates with cellulitis and no systemic findings, we provide coverage for GBS<em> </em>and other beta-hemolytic streptococci in addition to MRSA (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>). Empiric parenteral therapy options include <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> plus either an extended spectrum cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a> [if available], <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a>, <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftazidime</a>) or <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> (<a href=\"image.htm?imageKey=PEDS%2F107674\" class=\"graphic graphic_table graphicRef107674 \">table 3</a>).</p><p/><p class=\"headingAnchor\" id=\"H3683681263\"><span class=\"h3\">SSTI with systemic findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For neonates with suspected staphylococcal or streptococcal infection who have systemic findings (eg, fever, hypothermia, ill-appearance, irritability, poor feeding) it is usually necessary to add coverage for other neonatal pathogens (ie, <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a> [if available], <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftazidime</a>, or <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> for enteric gram-negative pathogens) (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>). The combination of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> plus one of these agents provides adequate empiric therapy for possible GBS cellulitis but is not appropriate for sepsis or meningitis (<a href=\"image.htm?imageKey=PEDS%2F107674\" class=\"graphic graphic_table graphicRef107674 \">table 3</a>). Appropriate antimicrobial regimens for neonatal sepsis and meningitis are discussed separately. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H7\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Etiologic agents'</a> and <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H4\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Initial empiric therapy'</a> and <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H27\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Antimicrobial therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H2391063259\"><span class=\"h2\">Duration of therapy</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>SSTI confined to the skin and soft tissues</strong> &mdash; The total duration of therapy for staphylococcal or streptococcal SSTI confined to the skin and soft tissues in neonates depends upon clinical response; a total of 7 to 14 days is usually adequate if there are no complications [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H303049436\" class=\"local\">'Response to therapy'</a> below.)</p><p/><p class=\"bulletIndent1\">For neonates with SSTI confined to the skin and soft tissues, we continue parenteral therapy at least until all of the following criteria are met (see <a href=\"#H303049436\" class=\"local\">'Response to therapy'</a> below):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Resolution of systemic symptoms and fever</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Improvement in other clinical findings</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Antibiotic susceptibility results are available if a pathogen is isolated</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Systemic bacterial cultures (eg, blood, urine, cerebrospinal fluid) isolate no pathogens during at least 48 hours of incubation</p><p/><p class=\"bulletIndent1\">Although we obtain blood cultures in preterm, low birth weight neonates with localized pustulosis, if blood cultures were not obtained, a five- to seven-day course of parenteral therapy is reasonable, provided that the infant continues to be clinically well and the pustulosis is completely resolved.</p><p/><p class=\"bulletIndent1\">Results of antibiotic susceptibility testing should be used to make decisions about which oral antibiotic to use for continuation of systemic therapy. Appropriate oral agents for neonates with SSTI include <a href=\"topic.htm?path=cephalexin-pediatric-drug-information\" class=\"drug drug_pediatric\">cephalexin</a> and <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, depending upon the susceptibilities of the isolate (<a href=\"image.htm?imageKey=PEDS%2F107674\" class=\"graphic graphic_table graphicRef107674 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Oral <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a> may be used when the isolate is resistant to other agents, but, given its high cost, consultation with an expert in infectious diseases may be warranted to make sure that it is the only oral option [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3\" class=\"abstract_t\">3</a>]. If a pathogen is not isolated, we continue coverage with an oral agent with activity against both MRSA and MSSA (eg, clindamycin). <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Trimethoprim-sulfamethoxazole</a> should not be used in neonates because it may displace bilirubin, increasing the risk for bilirubin toxicity. (See <a href=\"topic.htm?path=evaluation-of-unconjugated-hyperbilirubinemia-in-term-and-late-preterm-infants#H21\" class=\"medical medical_review\">&quot;Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants&quot;, section on 'Unbound bilirubin: Bilirubin/albumin ratio'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Invasive infection</strong> &mdash; The duration of antimicrobial therapy for neonates with staphylococcal or GBS infections that have extended beyond the skin and soft tissues is discussed separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections#H24\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections&quot;, section on 'Treatment of neonates'</a> and <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H27\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Antimicrobial therapy'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H303049436\"><span class=\"h1\">RESPONSE TO THERAPY</span></p><p class=\"headingAnchor\" id=\"H2676982012\"><span class=\"h2\">Monitoring response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Response to therapy is indicted by clinical improvement after 48 hours. In neonates who are admitted to the hospital for antimicrobial therapy, we monitor the skin and soft tissue infection (SSTI) for improvement or progression, the patient's vital signs, and culture and susceptibility results (if obtained).</p><p>Neonates who are treated for staphylococcal or streptococcal SSTI in the outpatient setting should be instructed to seek medical care promptly if they develop systemic symptoms (eg, fever, hypothermia, irritability, ill-appearance, poor feeding) or if local symptoms worsen [<a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/8\" class=\"abstract_t\">8</a>]. They should be seen for follow-up within 48 hours. Follow-up is essential to ensure clinical improvement and determine the need for drainage, additional drainage (if drained initially), or change in antimicrobial therapy.</p><p class=\"headingAnchor\" id=\"H1691103163\"><span class=\"h2\">Failure to respond</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initiation of systemic therapy (for neonates initially treated with topical antibiotics) or change in antimicrobial therapy (guided by culture and susceptibility results, if available) is indicated for neonates who worsen at any time during treatment and may be warranted for patients who remain stable but whose skin lesions have not improved after 48 hours of observation or antimicrobial therapy.</p><p>Possible explanations for failure to respond in neonates receiving an agent to which their isolate is susceptible include inadequate drainage (if drainage was performed), abscess recurrence, or development of a new abscess. Ultrasonography may identify residual, recurrent, or new abscesses that require drainage.</p><p>If cultures remain negative and ultrasonography does not identify lesions that require drainage, a change in empiric therapy may be indicated (eg, to include coverage for methicillin-resistant <em>S. aureus </em>[MRSA] if MRSA was not initially included). In such cases, consultation with an expert in infectious diseases is suggested.</p><p class=\"headingAnchor\" id=\"H716327276\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-skin-and-soft-tissue-infections\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Skin and soft tissue infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topic (see <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H943113269\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical evaluation of the neonate with suspected <em>Staphylococcus aureus</em> or streptococcal skin and soft tissue infection (SSTI) focuses on identification of systemic infection and clinical manifestations of conditions that require management that differs from the management of staphylococcal or streptococcal SSTI in neonates. These conditions often are associated with vesicopustular skin lesions (<a href=\"image.htm?imageKey=PEDS%2F75417\" class=\"graphic graphic_table graphicRef75417 \">table 1</a>). (See <a href=\"#H4050619578\" class=\"local\">'History and examination'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We obtain specimens for Gram stain, culture, and susceptibility testing from neonates with <span class=\"nowrap\">purulent/fluctuant</span> skin lesions (abscess) if purulent material can be obtained. Our approach to obtaining other laboratory studies and cultures in neonates with suspected bacterial SSTI depends upon the type of infection and associated clinical features. (See <a href=\"#H2484336351\" class=\"local\">'Laboratory evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For full term neonates with localized pustulosis (<a href=\"image.htm?imageKey=PEDS%2F107272\" class=\"graphic graphic_picture graphicRef107272 \">picture 1</a>) and no systemic findings (eg, temperature &ge;38&deg;C [100.4&deg;F] or &lt;35&deg;C [95&deg;F], ill-appearance, irritability, poor feeding), we suggest topical rather than systemic therapy (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We generally use <a href=\"topic.htm?path=mupirocin-pediatric-drug-information\" class=\"drug drug_pediatric\">mupirocin</a> three times daily for 5 to 10 days. Close outpatient follow-up is essential. (See <a href=\"#H3544538838\" class=\"local\">'Localized pustulosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We hospitalize preterm low birth weight neonates with localized pustulosis for parenteral therapy. We also hospitalize neonates with SSTI more severe than localized pustulosis (eg, pustulosis in multiple sites, cellulitis, abscess, mastitis) and neonates who undergo evaluation for serious bacterial infection (eg, bacteremia, urinary tract infection, meningitis, arthritis, osteomyelitis). (See <a href=\"#H3544538838\" class=\"local\">'Localized pustulosis'</a> above and <a href=\"#H2566049618\" class=\"local\">'SSTI more severe than localized pustulosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The empiric parenteral antibiotic regimen for suspected staphylococcal or streptococcal SSTI in neonates should be based upon the type of infection and local susceptibility pattern of community-associated <em>S. aureus</em> isolates (<a href=\"image.htm?imageKey=PEDS%2F113285\" class=\"graphic graphic_algorithm graphicRef113285 \">algorithm 1</a>). In areas with an increased prevalence of methicillin-resistant <em>S. aureus</em>, <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, and <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a> are appropriate alternatives for infection limited to the skin and soft tissues; <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a> (if available), <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftazidime</a>, or <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> may be added to broaden coverage (<a href=\"image.htm?imageKey=PEDS%2F107674\" class=\"graphic graphic_table graphicRef107674 \">table 3</a>). When the etiologic agent and susceptibility are known, antimicrobial therapy can be narrowed as indicated. (See <a href=\"#H986900721\" class=\"local\">'Choice of initial therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The duration of therapy for staphylococcal or streptococcal SSTI confined to the skin and soft tissues in neonates depends upon clinical response; a total of 7 to 14 days is usually adequate if there are no complications. (See <a href=\"#H2391063259\" class=\"local\">'Duration of therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/1\" class=\"nounderline abstract_t\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715.</li><li><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/3\" class=\"nounderline abstract_t\">Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.</a></li><li><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/4\" class=\"nounderline abstract_t\">Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.</a></li><li><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/5\" class=\"nounderline abstract_t\">Day CT, Kaplan SL, Mason EO, Hulten KG. Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old. Pediatr Infect Dis J 2014; 33:98.</a></li><li><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/6\" class=\"nounderline abstract_t\">Autret E, Laugier J, Marimbu J, et al. [Comparison of plasma levels of amoxicillin administered by oral and intravenous routes in neonatal bacterial colonization]. Arch Fr Pediatr 1988; 45:679.</a></li><li><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/7\" class=\"nounderline abstract_t\">Boothman R, Kerr MM, Marshall MJ, Burland WL. Absorption and excretion of cephalexin by the newborn infant. Arch Dis Child 1973; 48:147.</a></li><li><a href=\"https://www.uptodate.com/contents/suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-neonates-evaluation-and-management/abstract/8\" class=\"nounderline abstract_t\">Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008; 27:1.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 106447 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H943113269\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H4185297313\" id=\"outline-link-H4185297313\">INTRODUCTION</a></li><li><a href=\"#H3022346934\" id=\"outline-link-H3022346934\">ETIOLOGY</a></li><li><a href=\"#H82810968\" id=\"outline-link-H82810968\">EVALUATION</a><ul><li><a href=\"#H4050619578\" id=\"outline-link-H4050619578\">History and examination</a></li><li><a href=\"#H2484336351\" id=\"outline-link-H2484336351\">Laboratory evaluation</a></li></ul></li><li><a href=\"#H1383900093\" id=\"outline-link-H1383900093\">MANAGEMENT APPROACH</a><ul><li><a href=\"#H3544538838\" id=\"outline-link-H3544538838\">Localized pustulosis</a></li><li><a href=\"#H2566049618\" id=\"outline-link-H2566049618\">SSTI more severe than localized pustulosis</a></li></ul></li><li><a href=\"#H2164651994\" id=\"outline-link-H2164651994\">ANTIMICROBIAL THERAPY</a><ul><li><a href=\"#H986900721\" id=\"outline-link-H986900721\">Choice of initial therapy</a><ul><li><a href=\"#H667914192\" id=\"outline-link-H667914192\">- SSTI without systemic findings</a></li><li><a href=\"#H3683681263\" id=\"outline-link-H3683681263\">- SSTI with systemic findings</a></li></ul></li><li><a href=\"#H2391063259\" id=\"outline-link-H2391063259\">Duration of therapy</a></li></ul></li><li><a href=\"#H303049436\" id=\"outline-link-H303049436\">RESPONSE TO THERAPY</a><ul><li><a href=\"#H2676982012\" id=\"outline-link-H2676982012\">Monitoring response</a></li><li><a href=\"#H1691103163\" id=\"outline-link-H1691103163\">Failure to respond</a></li></ul></li><li><a href=\"#H716327276\" id=\"outline-link-H716327276\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H1905713806\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H943113269\" id=\"outline-link-H943113269\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/106447|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/113285\" class=\"graphic graphic_algorithm\">- Initial antibiotics for staph and strep SSTI in neonates</a></li></ul></li><li><div id=\"PEDS/106447|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/107272\" class=\"graphic graphic_picture\">- Staphylococcal pustulosis</a></li></ul></li><li><div id=\"PEDS/106447|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/75417\" class=\"graphic graphic_table\">- Differential diagnosis blister pustule infant</a></li><li><a href=\"image.htm?imageKey=PEDS/76743\" class=\"graphic graphic_table\">- Characteristic features of congenital infections</a></li><li><a href=\"image.htm?imageKey=PEDS/107674\" class=\"graphic graphic_table\">- Rx suspected S. aureus and streptococcal SSTI neonates</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-syphilis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Congenital syphilis: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-unconjugated-hyperbilirubinemia-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-outpatient-evaluation\" class=\"medical medical_review\">Febrile infant (younger than 90 days of age): Outpatient evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy\" class=\"medical medical_review\">Genital herpes simplex virus infection and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants\" class=\"medical medical_review\">Group B streptococcal infection in neonates and young infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Management and outcome of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mastitis-and-breast-abscess-in-infants-younger-than-two-months\" class=\"medical medical_review\">Mastitis and breast abscess in infants younger than two months</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-prevention-and-control\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus in children: Prevention and control</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-and-infantile-erythroderma\" class=\"medical medical_review\">Neonatal and infantile erythroderma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">Neonatal herpes simplex virus infection: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-the-basics\" class=\"medical medical_basics\">Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-detection-of-methicillin-resistant-staphylococcus-aureus\" class=\"medical medical_review\">Rapid detection of methicillin-resistant Staphylococcus aureus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-skin-and-soft-tissue-infections\" class=\"medical medical_society_guidelines\">Society guideline links: Skin and soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-children-greater-than28-days-evaluation-and-management\" class=\"medical medical_review\">Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in children &gt;28 days: Evaluation and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=varicella-zoster-infection-in-the-newborn\" class=\"medical medical_review\">Varicella-zoster infection in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant\" class=\"medical medical_review\">Vesiculopustular and bullous lesions in the newborn and infant</a></li></ul></div></div>","javascript":null}